Stocksigma LogoStocksigma Logo

Beta Drugs Secures Key Oncology Portfolio Approvals in Azerbaijan Market

Beta Drugs received regulatory approvals in Azerbaijan for its oncology portfolio across liquid injectables, lyophilised injectables, tablets, capsules

Beta Drugs Secures Key Oncology Portfolio Approvals in Azerbaijan Market

Beta Drugs Ltd 路 Others (Uncategorized) 路 22 Sept 2026, 2:30 pm

Beta Drugs Secures Key Oncology Portfolio Approvals in Azerbaijan Market Beta Drugs received regulatory approvals in Azerbaijan for its oncology portfolio across liquid injectables, lyophilised injectables, tablets, capsules, and oral suspensions. The company has filed 15 oncology dossiers, with an additional 15 products ready for filing next month. Positioned to be among the few oncology players in the country, Beta Drugs is targeting commercialisation and initial business generation during the current financial year, aligning with its broader strategy to expand its international oncology franchise across emerging global markets.

Original exchange filing (PDF)

More announcements from Beta Drugs Ltd

All Beta Drugs Ltd announcements